Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




High Throughput System Automates Human Papillomavirus HR Test

By LabMedica International staff writers
Posted on 26 Dec 2011
A high throughput system automates the DNA extraction and detection steps of the Human Papillomavirus high risk (HPV HR) test allowing users to walk away after loading the instrument and return the next morning to review the test results.

The Hologic (Bedford, MA, USA) HPV HR test utilizes the Invader technology to detect 14 high-risk types of HPV that are associated with cervical cancer and precancerous lesions.
The US Food and Drug Administration (FDA; Silver Spring, MD, USA have approved the Cervista high throughput automation system for cervical cancer screening.

Better diagnosis and therapies have helped to reduce significantly the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV. More...
Next to breast cancer, cervical cancer remains the second most frequent cancer affecting women worldwide.

"Our new Cervista represents a significant addition to our molecular diagnostics product portfolio," said Rob Cascella, president and CEO of Hologic. "The Cervista HTA automation system automates the HPV HR test, providing higher throughput, improved chain of custody, and accurate results. We are extremely pleased to get this product approved as it materially changes the competitive landscape for Hologic."

Related Links:

Hologic
US Food and Drug Administration





Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.